Canakinumab Add-on Treatment for Schizophrenia (CATS) Study

Canakinumab adjunctive treatment to reduce symptoms and improve cognition in people with schizophrenia displaying elevated blood inflammatory markers. You are invited to participate in a research study using a human immune cell-line antibody to improve language, memory, and reduce symptoms of schizophrenia. This human immune cell-line antibody, canakinumab, is a class of medication that decreases the levels of a protein called interleukin-1beta (IL-1β). The IL-1β protein is produced in response to inflammation in your body and canakinumab can decrease IL-1β protein and inflammation by blocking the pathway. We hope to learn how this human immune cell-line antibody, in addition to standard antipsychotic medication, can improve thought processing and reduce symptoms in people with schizophrenia, and to determine if this human immune cell-line antibody can be used as a new therapeutic treatment for people with schizophrenia. Further information here.